Skip to main content

Table 1 Patient characteristics at baseline per dose level

From: Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction

Characteristics

Dose level

 
 

1

2

3

Total

Number of patients

4 (100%)

13 (100%)

7 (100%)

24 (100%)

Age, years

    

N

4

13

6

23

Median (range)

55.5 (38–75)

65.0 (33–70)

56.0 (44–63)

62.0 (33–75)

Gender, n (%)

    

  Female

1 (25%)

2 (15%)

 

3 (13%)

  Male

3 (75%)

11 (85%)

7 (100%)

21 (88%)

KPS

    

  N

3

12

7

22

  Median (range)

100 (100–100)

90 (90–100)

100 (90–100)

95 (90–100)

Siewert classification

    

  AEG II

2 (50%)

9 (69%)

7 (100%)

18 (75%)

  AEG III

2 (50%)

4 (31%)

 

6 (25%)

T staging

    

3

3 (75%)

10 (77%)

6 (86%)

19 (79%)

4

1 (25%)

2 (15%)

1 (14%)

4 (17%)

X

 

1 (8%)

 

1 (4%)

N staging

    

0

 

2 (15%)

 

2 (8%)

1

2 (50%)

5 (38%)

4 (57%)

11 (46%)

2

2 (50%)

4 (31%)

2 (29%)

8 (33%)

X

 

2 (15%)

1 (14%)

3 (13%)

M staging

    

0

3 (75%)

12 (92%)

7 (100%)

22 (92%)

X

1 (25%)

1 (8%)

 

2 (8%)

UICC staging

    

II A

 

2 (15%)

 

2 (8%)

III

4 (100%)

8 (62%)

6 (86%)

18 (75%)

NK

 

3 (23%)

1 (14%)

4 (17%)

  1. KPS, Karnofsky Performance Status.
  2. UICC staging according to the 6th edition: NK in case of unknown T or N staging (Tx, Nx).
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us